Vista Capital Partners Inc. Sells 3,000 Shares of Absci Co. (NASDAQ:ABSI)

Vista Capital Partners Inc. lowered its holdings in shares of Absci Co. (NASDAQ:ABSI) by 5.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 55,317 shares of the company’s stock after selling 3,000 shares during the period. Vista Capital Partners Inc.’s holdings in Absci were worth $145,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABSI. ARK Investment Management LLC boosted its holdings in shares of Absci by 15.1% during the third quarter. ARK Investment Management LLC now owns 6,337,622 shares of the company’s stock worth $24,210,000 after acquiring an additional 833,734 shares during the period. Fred Alger Management LLC boosted its holdings in shares of Absci by 4.3% during the third quarter. Fred Alger Management LLC now owns 7,566,618 shares of the company’s stock worth $28,904,000 after acquiring an additional 309,843 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Absci by 28.5% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,143,829 shares of the company’s stock worth $2,997,000 after acquiring an additional 253,985 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Absci during the third quarter worth approximately $724,000. Finally, FMR LLC boosted its holdings in shares of Absci by 1.2% during the third quarter. FMR LLC now owns 12,727,760 shares of the company’s stock worth $48,620,000 after acquiring an additional 147,156 shares during the period. Institutional investors own 52.05% of the company’s stock.

Analyst Upgrades and Downgrades

ABSI has been the subject of a number of research analyst reports. KeyCorp reduced their price objective on Absci from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Guggenheim reiterated a “buy” rating and issued a $10.00 price target on shares of Absci in a research report on Tuesday, December 3rd. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Absci in a research report on Friday, January 17th. Finally, Needham & Company LLC started coverage on shares of Absci in a research report on Wednesday, January 22nd. They issued a “buy” rating and a $9.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $8.57.

Absci Stock Performance

NASDAQ ABSI opened at $5.79 on Wednesday. The firm’s fifty day moving average price is $3.65 and its two-hundred day moving average price is $3.73. The stock has a market cap of $665.04 million, a PE ratio of -6.23 and a beta of 2.11. Absci Co. has a fifty-two week low of $2.45 and a fifty-two week high of $6.72. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63.

Absci Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.